TB-500
A synthetic fragment of thymosin beta-4 studied for tissue repair and angiogenesis.
Research-only·Regulatory status as of May 2026
Relevance for women
A thymosin beta-4 fragment studied for tissue repair and recovery. Animal data; no completed human RCTs. Removed from FDA Category 2 in April 2026; PCAC review pending.
Articles on TB-500
Peptides for Recovery & Joint Health: BPC-157 Explained
BPC-157 is one of the most-discussed recovery peptides. Here's what the research shows, what the 2026 FDA changes mean, and an honest look at the evidence gaps.
Compounded vs. Research Peptides: What's Legal and What's Safe in 2026
The difference between a compounded peptide prescription and a gray-market 'research' peptide is the difference between regulated and unregulated. Here's what changed in 2026.
Providers that offer TB-500
See the full provider comparison for all peptides side by side.